A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Trial Profile

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 May 2018

At a glance

  • Drugs Filgotinib (Primary) ; Adalimumab; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms FINCH 1
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 27 Apr 2018 Planned End Date changed from 1 Feb 2020 to 1 Apr 2019.
    • 27 Apr 2018 Status changed from recruiting to active, no longer recruiting.
    • 25 Apr 2018 According to a Galapagos NV media release, Gilead expects to complete the recruitment of this study in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top